{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:35:19Z","timestamp":1783974919090,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,23]]},"DOI":"10.7759\/cureus.81034","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T15:47:30Z","timestamp":1742744850000},"source":"Crossref","is-referenced-by-count":4,"title":["Recent Advances in the Management of Dyslipidemia: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Huang","family":"Jacky Xiao Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousaf","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon","family":"Julie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ramiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uppal","family":"Krishma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhakar","family":"Pemminati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab037","article-title":"A modern approach to dyslipidemia","volume":"43","author":"Berberich AJ","year":"2022","unstructured":"Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022, 43:611-53. 10.1210\/endrev\/bnab037","journal-title":"Endocr Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2023.05.002","article-title":"Dyslipidemia update","volume":"58","author":"Ballard-Hernandez J","year":"2023","unstructured":"Ballard-Hernandez J, Sall J. Dyslipidemia update. Nurs Clin North Am. 2023, 58:295-308. 10.1016\/j.cnur.2023.05.002","journal-title":"Nurs Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164716","article-title":"Current options and future perspectives in the treatment of dyslipidemia","volume":"11","author":"Muscoli S","year":"2022","unstructured":"Muscoli S, Ifrim M, Russo M, et al.. Current options and future perspectives in the treatment of dyslipidemia. J Clin Med. 2022, 11:4716. 10.3390\/jcm11164716","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030809","article-title":"Hyperlipidemia and cardiovascular risk in children and adolescents","volume":"11","author":"Mainieri F","year":"2023","unstructured":"Mainieri F, La Bella S, Chiarelli F. Hyperlipidemia and cardiovascular risk in children and adolescents. Biomedicines. 2023, 11:809. 10.3390\/biomedicines11030809","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n J","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020, 41:2313-30. 10.1093\/eurheartj\/ehz962","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147310","article-title":"Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia","volume":"22","author":"Chen PY","year":"2021","unstructured":"Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021, 22:7310. 10.3390\/ijms22147310","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins R","year":"2016","unstructured":"Collins R, Reith C, Emberson J, et al.. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016, 388:2532-61. 10.1016\/S0140-6736(16)31357-5","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0163","article-title":"Comparative efficacy and safety among high-intensity statins. Systematic review and meta-analysis","volume":"12","author":"Jaam M","year":"2023","unstructured":"Jaam M, Al-Naimi HN, Haddad MM, Abushanab D, Al-Badriyeh D. Comparative efficacy and safety among high-intensity statins. Systematic review and meta-analysis. J Comp Eff Res. 2023, 12:e220163. 10.57264\/cer-2022-0163","journal-title":"J Comp Eff Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-6-5","article-title":"Bempedoic acid for the treatment of dyslipidemia","volume":"9","author":"Marrs JC","year":"2020","unstructured":"Marrs JC, Anderson SL. Bempedoic acid for the treatment of dyslipidemia. Drugs Context. 2020, 9:2020-6-5. 10.7573\/dic.2020-6-5","journal-title":"Drugs Context"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S332352","article-title":"Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: Current insights","volume":"16","author":"Chilbert MR","year":"2022","unstructured":"Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: Current insights. Drug Des Devel Ther. 2022, 16:2177-86. 10.2147\/DDDT.S332352","journal-title":"Drug Des Devel Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska B","year":"2022","unstructured":"Sosnowska B, Adach W, Surma S, Rosenson RS, Banach M. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia. J Clin Med. 2022, 12:168. 10.3390\/jcm12010168","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0198","article-title":"New, novel lipid-lowering agents for reducing cardiovascular risk: Beyond statins","volume":"46","author":"Kim K","year":"2022","unstructured":"Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: Beyond statins. Diabetes Metab J. 2022, 46:517-32. 10.4093\/dmj.2022.0198","journal-title":"Diabetes Metab J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(93)90264-u","article-title":"Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules","volume":"103","author":"Frosteg\u00e5rd J","year":"1993","unstructured":"Frosteg\u00e5rd J, Wu R, Haegerstrand A, Patarroyo M, Lefvert AK, Nilsson J. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis. 1993, 103:213-9. 10.1016\/0021-9150(93)90264-u","journal-title":"Atherosclerosis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2302073","article-title":"Biomarkers of endothelial activation and dysfunction in cardiovascular diseases","volume":"23","author":"Zhang J","year":"2022","unstructured":"Zhang J. Biomarkers of endothelial activation and dysfunction in cardiovascular diseases. Rev Cardiovasc Med. 2022, 23:73. 10.31083\/j.rcm2302073","journal-title":"Rev Cardiovasc Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.785220","article-title":"Roles of macrophages in atherogenesis","volume":"12","author":"Farahi L","year":"2021","unstructured":"Farahi L, Sinha SK, Lusis AJ. Roles of macrophages in atherogenesis. Front Pharmacol. 2021, 12:785220. 10.3389\/fphar.2021.785220","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306256","article-title":"Macrophage phenotype and function in different stages of atherosclerosis","volume":"118","author":"Tabas I","year":"2016","unstructured":"Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res. 2016, 118:653-67. 10.1161\/CIRCRESAHA.115.306256","journal-title":"Circ Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-344","article-title":"Interlinking pathways: A narrative review on the role of IL-6 in cancer and atherosclerosis","volume":"14","author":"Cau R","year":"2024","unstructured":"Cau R, Saba L. Interlinking pathways: A narrative review on the role of IL-6 in cancer and atherosclerosis. Cardiovasc Diagn Ther. 2024, 14:1186-201. 10.21037\/cdt-24-344","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker PM","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: Moving upstream to identify novel targets for atheroprotection. Circ Res. 2016, 118:145-56. 10.1161\/CIRCRESAHA.115.306656","journal-title":"Circ Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.26717\/BJSTR.2022.43.006869","article-title":"Pathophysiology and management of dyslipidemia","volume":"43","author":"Bereda G","year":"2022","unstructured":"Bereda G. Pathophysiology and management of dyslipidemia. Biomed J Sci Tech Res. 2022, 43:34369-75. 10.26717\/BJSTR.2022.43.006869","journal-title":"Biomed J Sci Tech Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-019-0169-2","article-title":"Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities","volume":"16","author":"B\u00e4ck M","year":"2019","unstructured":"B\u00e4ck M, Yurdagul A Jr, Tabas I, \u00d6\u00f6rni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. Nat Rev Cardiol. 2019, 16:389-406. 10.1038\/s41569-019-0169-2","journal-title":"Nat Rev Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-019-0097-4","article-title":"A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity","volume":"4","author":"Rosa M","year":"2019","unstructured":"Rosa M, Chignon A, Li Z, et al.. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. NPJ Genom Med. 2019, 4:23. 10.1038\/s41525-019-0097-4","journal-title":"NPJ Genom Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111687","article-title":"Statin-associated myopathy: Emphasis on mechanisms and targeted therapy","volume":"22","author":"Vinci P","year":"2021","unstructured":"Vinci P, Panizon E, Tosoni LM, et al.. Statin-associated myopathy: Emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021, 22:11687. 10.3390\/ijms222111687","journal-title":"Int J Mol Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002551","article-title":"Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS)","volume":"11","author":"Mangone LA","year":"2024","unstructured":"Mangone LA, Taylor BA, Schmelzer R, Noh SG, White MC, Kwon OS, Thompson PD. Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS). Open Heart. 2024, 11:e002551. 10.1136\/openhrt-2023-002551","journal-title":"Open Heart"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.121.003503","article-title":"Pharmacogenomic study of statin-associated muscle symptoms in the ODYSSEY OUTCOMES Trial","volume":"15","author":"Murphy WA","year":"2022","unstructured":"Murphy WA, Lin N, Damask A, et al.. Pharmacogenomic study of statin-associated muscle symptoms in the ODYSSEY OUTCOMES Trial. Circ Genom Precis Med. 2022, 15:e003503. 10.1161\/CIRCGEN.121.003503","journal-title":"Circ Genom Precis Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.4250","article-title":"Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo","volume":"8","author":"Hlatky MA","year":"2023","unstructured":"Hlatky MA, Gonzalez PE, Manson JE, et al.. Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo. JAMA Cardiol. 2023, 8:74-80. 10.1001\/jamacardio.2022.4250","journal-title":"JAMA Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011320","article-title":"Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study","volume":"8","author":"Ko MJ","year":"2019","unstructured":"Ko MJ, Jo AJ, Kim YJ, et al.. Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study. J Am Heart Assoc. 2019, 8:e011320. 10.1161\/JAHA.118.011320","journal-title":"J Am Heart Assoc"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial","volume":"400","author":"Kim BK","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, et al.. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial. Lancet. 2022, 400:380-90. 10.1016\/S0140-6736(22)00916-3","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2023.243","article-title":"Expanding the therapeutic landscape: Ezetimibe as non-statin therapy for dyslipidemia","volume":"38","author":"Lee J","year":"2023","unstructured":"Lee J, Lee SH. Expanding the therapeutic landscape: Ezetimibe as non-statin therapy for dyslipidemia. Korean J Intern Med. 2023, 38:797-809. 10.3904\/kjim.2023.243","journal-title":"Korean J Intern Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179727","article-title":"Hypertriglyceridemia therapy: Past, present and future perspectives","volume":"25","author":"Canfora I","year":"2024","unstructured":"Canfora I, Pierno S. Hypertriglyceridemia therapy: Past, present and future perspectives. Int J Mol Sci. 2024, 25:9727. 10.3390\/ijms25179727","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-014-3344-3","article-title":"Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"57","author":"d'Emden MC","year":"2014","unstructured":"d'Emden MC, Jenkins AJ, Li L, et al.. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2014, 57:2296-303. 10.1007\/s00125-014-3344-3","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11040140","article-title":"Effectiveness and safety of fenofibrate in routine treatment of patients with hypertriglyceridemia and metabolic syndrome","volume":"11","author":"Ezhov MV","year":"2023","unstructured":"Ezhov MV, Arutyunov GP. Effectiveness and safety of fenofibrate in routine treatment of patients with hypertriglyceridemia and metabolic syndrome. Diseases. 2023, 11:140. 10.3390\/diseases11040140","journal-title":"Diseases"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/ehjopen\/oeae032","article-title":"Dyslipidaemia management in pregnant patients: A 2024 update","volume":"4","author":"Lewek J","year":"2024","unstructured":"Lewek J, Bielecka-D\u0105browa A, Toth PP, Banach M. Dyslipidaemia management in pregnant patients: A 2024 update. Eur Heart J Open. 2024, 4:oeae032. 10.1093\/ehjopen\/oeae032","journal-title":"Eur Heart J Open"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0571-8","article-title":"Gemfibrozil in combination with statins-Is it really contraindicated?","volume":"18","author":"Wiggins BS","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Morris PB. Gemfibrozil in combination with statins-Is it really contraindicated?. Curr Atheroscler Rep. 2016, 18:18. 10.1007\/s11883-016-0571-8","journal-title":"Curr Atheroscler Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-013-1188-0","article-title":"Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPAR\u03b1 and its relevance to hepatotoxicity","volume":"88","author":"Liu A","year":"2014","unstructured":"Liu A, Krausz KW, Fang ZZ, Brocker C, Qu A, Gonzalez FJ. Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPAR\u03b1 and its relevance to hepatotoxicity. Arch Toxicol. 2014, 88:983-96. 10.1007\/s00204-013-1188-0","journal-title":"Arch Toxicol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.08.017","article-title":"Efficacy and safety of lomitapide in familial chylomicronaemia syndrome","volume":"359","author":"Cefal\u00f9 AB","year":"2022","unstructured":"Cefal\u00f9 AB, D'Erasmo L, Iannuzzo G, et al.. Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis. 2022, 359:13-9. 10.1016\/j.atherosclerosis.2022.08.017","journal-title":"Atherosclerosis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102367","article-title":"Intensive combination LDL-lowering therapy in a patient with homozygous familial hypercholesterolemia","volume":"29","author":"Tada H","year":"2024","unstructured":"Tada H, Okada H, Kawashiri MA, Takamura M. Intensive combination LDL-lowering therapy in a patient with homozygous familial hypercholesterolemia. JACC Case Rep. 2024, 29:102367. 10.1016\/j.jaccas.2024.102367","journal-title":"JACC Case Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-015-0006-5","article-title":"Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome","volume":"14","author":"Meyers CD","year":"2015","unstructured":"Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids Health Dis. 2015, 14:8. 10.1186\/s12944-015-0006-5","journal-title":"Lipids Health Dis"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57157-5","article-title":"Treatment of human skeletal muscle cells with inhibitors of diacylglycerol acyltransferases 1 and 2 to explore isozyme-specific roles on lipid metabolism","volume":"10","author":"L\u00f8vsletten NG","year":"2020","unstructured":"L\u00f8vsletten NG, Vu H, Skagen C, et al.. Treatment of human skeletal muscle cells with inhibitors of diacylglycerol acyltransferases 1 and 2 to explore isozyme-specific roles on lipid metabolism. Sci Rep. 2020, 10:238. 10.1038\/s41598-019-57157-5","journal-title":"Sci Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.12.008","article-title":"Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: Potential therapeutic implications of pharmacology","volume":"45","author":"Amin NB","year":"2023","unstructured":"Amin NB, Saxena AR, Somayaji V, Dullea R. Inhibition of diacylglycerol acyltransferase 2 versus diacylglycerol acyltransferase 1: Potential therapeutic implications of pharmacology. Clin Ther. 2023, 45:55-70. 10.1016\/j.clinthera.2022.12.008","journal-title":"Clin Ther"},{"key":"ref41","article-title":"Antilipemic agent bile acid sequestrants","author":"Lent-Schochet D","year":"2023","unstructured":"Lent-Schochet D, Jialal I. Antilipemic agent bile acid sequestrants. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0174-4","article-title":"Safety and efficacy of colesevelam HCl in the treatment of elderly patients","volume":"31","author":"Gavin JR 3rd","year":"2014","unstructured":"Gavin JR 3rd, Jones MR, Ford DM, Truitt KE. Safety and efficacy of colesevelam HCl in the treatment of elderly patients. Drugs Aging. 2014, 31:461-70. 10.1007\/s40266-014-0174-4","journal-title":"Drugs Aging"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.001","article-title":"Nonstatin therapies for management of dyslipidemia: A review","volume":"37","author":"Sando KR","year":"2015","unstructured":"Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: A review. Clin Ther. 2015, 37:2153-79. 10.1016\/j.clinthera.2015.09.001","journal-title":"Clin Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00416.2016","article-title":"Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated","volume":"313","author":"Sj\u00f6berg BG","year":"2017","unstructured":"Sj\u00f6berg BG, Straniero S, Angelin B, Rudling M. Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. Am J Physiol Endocrinol Metab. 2017, 313:E167-74. 10.1152\/ajpendo.00416.2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1702970","article-title":"PCSK9 inhibitors for treating hypercholesterolemia","volume":"21","author":"Pasta A","year":"2020","unstructured":"Pasta A, Cremonini AL, Pisciotta L, et al.. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 2020, 21:353-63. 10.1080\/14656566.2019.1702970","journal-title":"Expert Opin Pharmacother"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2018.1441255","article-title":"Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia","volume":"31","author":"Zhang J","year":"2018","unstructured":"Zhang J, Tecson KM, Rocha NA, McCullough PA. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia. Proc (Bayl Univ Med Cent). 2018, 31:180-4. 10.1080\/08998280.2018.1441255","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial","volume":"324","author":"Nicholls SJ","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, et al.. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA. 2020, 324:2268-80. 10.1001\/jama.2020.22258","journal-title":"JAMA"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.10.018","article-title":"Dietary niacin intake and risk of dyslipidemia: A pooled analysis of three prospective cohort studies","volume":"41","author":"Kim C","year":"2022","unstructured":"Kim C, Park K. Dietary niacin intake and risk of dyslipidemia: A pooled analysis of three prospective cohort studies. Clin Nutr. 2022, 41:2749-58. 10.1016\/j.clnu.2022.10.018","journal-title":"Clin Nutr"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1177\/1074248413514481","article-title":"The therapeutic role of niacin in dyslipidemia management","volume":"19","author":"Boden WE","year":"2014","unstructured":"Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. J Cardiovasc Pharmacol Ther. 2014, 19:141-58. 10.1177\/1074248413514481","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S66521","article-title":"New advances in the treatment of generalized lipodystrophy: Role of metreleptin","volume":"11","author":"Rodriguez AJ","year":"2015","unstructured":"Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodystrophy: Role of metreleptin. Ther Clin Risk Manag. 2015, 11:1391-400. 10.2147\/TCRM.S66521","journal-title":"Ther Clin Risk Manag"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104085","article-title":"Complications of lipodystrophy syndromes","volume":"50","author":"Akinci G","year":"2021","unstructured":"Akinci G, Celik M, Akinci B. Complications of lipodystrophy syndromes. Presse Med. 2021, 50:104085. 10.1016\/j.lpm.2021.104085","journal-title":"Presse Med"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00103","article-title":"Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy","volume":"3","author":"Kinzer AB","year":"2019","unstructured":"Kinzer AB, Shamburek RD, Lightbourne M, Muniyappa R, Brown RJ. Advanced lipoprotein analysis shows atherogenic lipid profile that improves after metreleptin in patients with lipodystrophy. J Endocr Soc. 2019, 3:1503-17. 10.1210\/js.2019-00103","journal-title":"J Endocr Soc"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray KK","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al.. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019, 380:1022-32. 10.1056\/NEJMoa1803917","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita S","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: Drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020, 22:5. 10.1007\/s11883-020-0823-5","journal-title":"Curr Atheroscler Rep"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan A","year":"2022","unstructured":"Das Pradhan A, Glynn RJ, Fruchart JC, et al.. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022, 387:1923-34. 10.1056\/NEJMoa2210645","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart JC","year":"2017","unstructured":"Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017, 16:124. 10.1186\/s12933-017-0602-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-1037","article-title":"New trends in dyslipidemia treatment","volume":"85","author":"Jang AY","year":"2021","unstructured":"Jang AY, Lim S, Jo SH, Han SH, Koh KK. New trends in dyslipidemia treatment. Circ J. 2021, 85:759-68. 10.1253\/circj.CJ-20-1037","journal-title":"Circ J"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S338424","article-title":"Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease","volume":"19","author":"Albosta MS","year":"2023","unstructured":"Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: A new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc Health Risk Manag. 2023, 19:421-31. 10.2147\/VHRM.S338424","journal-title":"Vasc Health Risk Manag"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: The LIBerate-HeFH trial","volume":"44","author":"Raal F","year":"2023","unstructured":"Raal F, Fourie N, Scott R, et al.. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: The LIBerate-HeFH trial. Eur Heart J. 2023, 44:4272-80. 10.1093\/eurheartj\/ehad596","journal-title":"Eur Heart J"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolemia with PCSK9 inhibition (LIBerate-HoFH): A phase 3, randomized, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal FJ","year":"2025","unstructured":"Raal FJ, Mehta V, Kayikcioglu M, et al.. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolemia with PCSK9 inhibition (LIBerate-HoFH): A phase 3, randomized, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025, 13:178-87. 10.1016\/S2213-8587(24)00313-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref62","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118513","article-title":"Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD)","volume":"395","author":"Kereiakes DJ","year":"2024","unstructured":"Kereiakes DJ, Fourie N, Engelbrecht J, et al.. Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD). Atherosclerosis. 2024, 395:118513.","journal-title":"Atherosclerosis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia","volume":"391","author":"Ballantyne CM","year":"2024","unstructured":"Ballantyne CM, Vasas S, Azizad M, et al.. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med. 2024, 391:899-912. 10.1056\/NEJMoa2404143","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.04.101","article-title":"Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates deep and durable TG reductions in patients with SHTG: SHASTA-2 final results","volume":"18","author":"Pall D","year":"2024","unstructured":"Pall D, Watts GF, Nicholls SJ, et al.. Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates deep and durable TG reductions in patients with SHTG: SHASTA-2 final results. J Clin Lipidol. 2024, 18:e564. 10.1016\/j.jacl.2024.04.101","journal-title":"J Clin Lipidol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S120387","article-title":"Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects","volume":"10","author":"Kim CO","year":"2016","unstructured":"Kim CO, Oh ES, Choi C, Kim Y, Lee S, Kim S, Park MS. Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects. Drug Des Devel Ther. 2016, 10:3763-70. 10.2147\/DDDT.S120387","journal-title":"Drug Des Devel Ther"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial","volume":"17","author":"Ballantyne CM","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023, 17:491-503. 10.1016\/j.jacl.2023.05.098","journal-title":"J Clin Lipidol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.121.317181","article-title":"Pharmacological inhibition of CETP (cholesteryl ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease","volume":"42","author":"Furtado JD","year":"2022","unstructured":"Furtado JD, Ruotolo G, Nicholls SJ, Dullea R, Carvajal-Gonzalez S, Sacks FM. Pharmacological inhibition of CETP (cholesteryl ester transfer protein) increases HDL (high-density lipoprotein) that contains ApoC3 and other HDL subspecies associated with higher risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 2022, 42:227-37. 10.1161\/ATVBAHA.121.317181","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab863","article-title":"Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease","volume":"43","author":"Sammons E","year":"2022","unstructured":"Sammons E, Hopewell JC, Chen F, et al.. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022, 43:1416-24. 10.1093\/eurheartj\/ehab863","journal-title":"Eur Heart J"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0792-8","article-title":"Antisense oligonucleotides targeting lipoprotein(a)","volume":"21","author":"Langsted A","year":"2019","unstructured":"Langsted A, Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a). Curr Atheroscler Rep. 2019, 21:30. 10.1007\/s11883-019-0792-8","journal-title":"Curr Atheroscler Rep"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark BA","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al.. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024, 390:1770-80. 10.1056\/NEJMoa2402309","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel NO","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, et al.. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017, 69:2054-63. 10.1016\/j.jacc.2017.02.030","journal-title":"J Am Coll Cardiol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S345072","article-title":"Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia","volume":"14","author":"Kosmas CE","year":"2022","unstructured":"Kosmas CE, Bousvarou MD, Sourlas A, Papakonstantinou EJ, Pe\u00f1a Genao E, Echavarria Uceta R, Guzman E. Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia. Clin Pharmacol. 2022, 14:49-59. 10.2147\/CPAA.S345072","journal-title":"Clin Pharmacol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100446","article-title":"Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia","volume":"2","author":"Fukami H","year":"2021","unstructured":"Fukami H, Morinaga J, Nakagami H, et al.. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Rep Med. 2021, 2:100446. 10.1016\/j.xcrm.2021.100446","journal-title":"Cell Rep Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.020","article-title":"A novel \u03c9-3 acid ethyl ester formulation incorporating advanced lipid technologies(TM) (ALT(\u00ae)) improves docosahexaenoic acid and eicosapentaenoic acid bioavailability compared with Lovaza(\u00ae)","volume":"39","author":"Lopez-Toledano MA","year":"2017","unstructured":"Lopez-Toledano MA, Thorsteinsson T, Daak A, Maki KC, Johns C, Rabinowicz AL, Sancilio FD. A novel \u03c9-3 acid ethyl ester formulation incorporating advanced lipid technologies(TM) (ALT(\u00ae)) improves docosahexaenoic acid and eicosapentaenoic acid bioavailability compared with Lovaza(\u00ae). Clin Ther. 2017, 39:581-91. 10.1016\/j.clinthera.2017.01.020","journal-title":"Clin Ther"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV16001","article-title":"Development of antisense drugs for dyslipidemia","volume":"23","author":"Yamamoto T","year":"2016","unstructured":"Yamamoto T, Wada F, Harada-Shiba M. Development of antisense drugs for dyslipidemia. J Atheroscler Thromb. 2016, 23:1011-25. 10.5551\/jat.RV16001","journal-title":"J Atheroscler Thromb"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22187","article-title":"Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights","volume":"85","author":"Ers\u00f6z E","year":"2024","unstructured":"Ers\u00f6z E, Demir-Dora D. Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights. Drug Dev Res. 2024, 85:e22187. 10.1002\/ddr.22187","journal-title":"Drug Dev Res"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2022.06.075","article-title":"ETESIAN: A phase 2B study of the efficacy, safety, and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia","volume":"355","author":"Hofherr A","year":"2022","unstructured":"Hofherr A, Schumi J, Reki\u0107 D, et al.. ETESIAN: A phase 2B study of the efficacy, safety, and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis. 2022, 355:28. 10.1016\/j.atherosclerosis.2022.06.075","journal-title":"Atherosclerosis"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155082","article-title":"Targeting PCSK9 and beyond for the management of low-density lipoprotein cholesterol","volume":"12","author":"Mohamed F","year":"2023","unstructured":"Mohamed F, Mansfield B, Raal FJ. Targeting PCSK9 and beyond for the management of low-density lipoprotein cholesterol. J Clin Med. 2023, 12:5082. 10.3390\/jcm12155082","journal-title":"J Clin Med"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham MJ","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, et al.. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017, 377:222-32. 10.1056\/NEJMoa1701329","journal-title":"N Engl J Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet D","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al.. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020, 41:3936-45. 10.1093\/eurheartj\/ehaa689","journal-title":"Eur Heart J"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000898","article-title":"Angiopoietin-like 3 inhibition and the liver: Less is more?","volume":"34","author":"Oostveen RF","year":"2023","unstructured":"Oostveen RF, Hovingh GK, Stroes ES. Angiopoietin-like 3 inhibition and the liver: Less is more?. Curr Opin Lipidol. 2023, 34:267-71. 10.1097\/MOL.0000000000000898","journal-title":"Curr Opin Lipidol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular efficacy and safety of bococizumab in high-risk patients","volume":"376","author":"Ridker PM","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, et al.. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017, 376:1527-39. 10.1056\/NEJMoa1701488","journal-title":"N Engl J Med"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00846-x","article-title":"Anti-drug antibody magnitude and clinical relevance using signal to noise (S\/N): Bococizumab case study","volume":"25","author":"McCush F","year":"2023","unstructured":"McCush F, Wang E, Yunis C, Schwartz P, Baltrukonis D. Anti-drug antibody magnitude and clinical relevance using signal to noise (S\/N): Bococizumab case study. AAPS J. 2023, 25:85. 10.1208\/s12248-023-00846-x","journal-title":"AAPS J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334268-recent-advances-in-the-management-of-dyslipidemia-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T15:47:50Z","timestamp":1742744870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334268-recent-advances-in-the-management-of-dyslipidemia-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,23]]},"references-count":83,"URL":"https:\/\/doi.org\/10.7759\/cureus.81034","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,23]]}}}